

MIRACLE

LEUKEMIA



MidTerm Meeting

20 January 2026

ADORE - RDC Building | Room 't IJ - 2nd floor
Van der Boechorststraat 6B, 1081 BT Amsterdam

Agenda & Proceedings



MidTerm Meeting

MIRACLE Leukemia MSCA Doctoral Network

It is our pleasure to welcome you all to the MIRACLE MidTerm Meeting. We are proud to gather AT January 20th, to reflect on the progress we have made together in our mission to “*Combat minimal residual disease (MRD) to revolutionize leukemia treatment*”.

This meeting marks an important milestone in our journey. Over the past months, our consortium of dedicated researchers, clinicians, and partners from across Europe has laid a strong foundation—scientifically, collaboratively, and in training the next generation of experts.

We warmly thank our EU Project Officer for her continued support and guidance, and we would like to express our sincere appreciation to all project participants for your commitment, and innovative spirit.

Let us use this meeting not only to report on our progress, but to strengthen our connections, share our insights, and align our next steps toward achieving the ambitious goals of MIRACLE.

Dr. Linda Smit
Project Coordinator

Prof. Jacqueline Cloos
Co-Project Coordinator



Practical

- Wifi - find this account and connect via browser: Guest_KPN@VUmc
- Courses and presentations are recorded for internal purposes.
- Impression pictures are taken for the MIRACLE communications channels.
- For online participation and/or questions? Connect with Ellen de Waal, MIRACLE Project Manager [p.b.dewaal@amsterdamumc.nl]

Objectives

- Presenting the MIRACLE progress and achievements in terms of recruitment and management.
- Presentations of the individual research projects (IRPs) by the Doctoral Candidates (DCs).

Attendees

- The project coordination team
- The scientists-in-charge
- The representatives of the beneficiaries and Associated Partners
- The DCs
- Members of the Advisory Board and the Supervisory Board.

Chair: MIRACLE MSCA EU Project Officer, Stanka Miteva.

Co-chair: Dr. Linda Smit, Amsterdam UMC/Project Coordinator.



Agenda

08:30 - 09:00 hrs Registration

Plenary session

- 09:00-09:05 **Welcome and introduction**
- By **Stanka Miteva**, European Commission European Research Executive Agency (REA), MIRACLE MSCA Project Officer, and
 - By **Linda Smit**, Amsterdam UMC, MIRACLE Project Coordinator
- 09:05-09:35 **Tour the table**
- All MIRACLE scientists-in-charge (beneficiaries/supervisors) briefly present their research team and describe their role within the network.
 - Introduction of the MIRACLE Associated Partners.
- 09:35-10:05 **MSCA EU Project officer presentation**
- By **Stanka Miteva**, EC REA
 - Topics: Monitoring of project implementation, reporting and purpose of the Mid-
- 10:05-11.00 **Progress Report presentation**
- By **Linda Smit**, Project Coordinator, Amsterdam UMC
 - Topics: Progress of the project including recruitment and management: State of play of the recruitment, deliverables and milestone.
- 11.00-11.15 *Coffee break in the RDC Coffee bar 't Binnenhof (same floor)*
- 11:15-12:45 **Individual Presentations of the DCs on their Individual Research Project (IRP)**
DCs will present themselves, their background and their individual research project (foreseen research, training, secondments, etc.). Scientific results are not expected in the presentations at this stage of the project
- 12.45-13.45 *Lunch break in the in the RDC Coffee bar 't Binnenhof (same floor)*

Parallel sessions

- 13.45-14.40 **Restricted session Stanka Miteva with the DCs** (*in room t IJ*)
- 13.45-14.40 **Supervisory Board meeting** (*in Meeting room: Div9 ZH4 J037 - 4th floor*)
- 13.45-14.40 **Advisory Board meeting** (*in Meeting room: Div9 ZH4 J036 - 4th floor*)
- 13.45-14.40 **Associated Partners and/or other attendees** are asked to take place in the RDC Coffee bar 't Binnenhof (same floor)

Extra meeting room available: Div9 HL BEBO 010 from 13:00-15:00 hrs.

Plenary session

All participants to assemble again in room t IJ

- 14.45-15.00 **Discussion with the Advisory Board**
- 15.00-15.30 **Feedback by REA EU Project Officer followed by discussion**
- 15.30-15.45 *Coffee break in the RDC Coffee bar 't Binnenhof (same floor)*
- 15.45-16.30 **Wrap up**
Including planning, communications & dissemination



About MIRACLE

Combat minimal residual disease (MRD) to revolutionize leukemia treatment

MIRACLE-Leukemia is a Marie Skłodowska-Curie doctoral network aiming to educate a new generation of researchers optimally equipped to advance and accelerate development of novel therapeutics directed to leukemia MRD, and to progress effective treatments to the clinic.

MIRACLE will elucidate the leukemia MRD landscape by integrating the knowledge on mechanisms driving persistence of MRD from different angles, and by the subsequent design of efficient and less toxic, novel targeted combination therapy with increased capacity to induce deep responses in patients.

MIRACLE is an international, multidisciplinary and multisectoral training program consisting of 23 academic and non-academic partners from 8 EU countries (The Netherlands, Belgium, Germany, France, Spain, Italy, Czech Republic, United Kingdom).


The project is coordinated by Dr. Linda Smit and Prof. Jacqueline Cloos of the Amsterdam UMC department of Hematology.

Funded by the European Union's Horizon Europe's Research and Innovation Program under the Marie Skłodowska-Curie Actions Grant Agreement nr. 101167512 -> www.miracle-leukemia.eu


MIRACLE Partners



Project structure



Project organisation and governance





Supervisory Board (SB)

| DC | Primary Supervisor(s) & Host Institution | Co-Supervisor(s) & Host Institution |
|------|--|---|
| DC1 | Jacqueline Cloos, Amsterdam UMC Costa Bachas, Amsterdam UMC John Jacobs, Ortec | Jan Stuchly, Charles University |
| DC2 | Jan Trka, Charles University Jan Stuchly, Charles University | Jacqueline Cloos, Amsterdam UMC |
| DC3 | Karla Queiroz, Mimetas Henriette Lanz, Mimetas | Linda Smit, Amsterdam UMC |
| DC4 | Linda Smit, Amsterdam UMC Rachel Thijssen, Amsterdam UMC | Jan Cools, VIB KU Leuven |
| DC5 | Jan Cools, VIB KU Leuven Sophie DeMeyer, VIB KU Leuven | Simon Mendez-Ferrer, University of Sevilla |
| DC6 | Alexandre Puissant, INSERM Matthieu Duchmann, INSERM | Karla Queiroz, Mimetas |
| DC7 | Simon Mendez, University of Sevilla Agate Chedeville, University of Sevilla | Marion Subklewe, LMU |
| DC8 | Raffaella DiMicco, San Raffael Antonella Santoro, San Raffael | Jan Henning Klusmann, Goethe University |
| DC9 | Jan H. Klusmann, Goethe University Dirk Heckl, Goethe University | Raffaella DiMicco, Ospedale San Raffael |
| DC10 | Marion Subklewe, LMU Ann-Sophie Neumann, LMU Daniel Nixdorf, LMU | Alexandre Puissant/Raphael Itzykson, INSERM |
| | | |
| | Rotating DCs | |
| | YR 1 Mai Huong Pham, Amsterdam UMC Nishika Gupta, INSERM YR 2 Nurbanu Erolmez, Mimetas Arif Kozac, KU Leuven YR 3 Maria Lopes, Ospedale San Raffael Pierluigi Carulli, LMU | |



Doctoral Candidates Committee (DCC)

| DC | Project | Name & Host Institute |
|------|--|---|
| DC1 | Optimizing treatment decisions by using MRD data combined with artificial intelligence | Mai Huong Pham Amsterdam UMC |
| DC2 | In-depth analysis of phenotypic acute leukemia MRD dynamics using single cell data and advance computer techniques | Alyssa Rodrigues Alvaro Charles University |
| DC3 | Establishment of clinical translational AML MRD on-chip models | Nurbanu Erölmez Mimetas |
| DC4 | Characterization of AML MRD using single cell transcriptomic and epigenetic analysis | Allessandro Gagliardi Amsterdam UMC |
| DC5 | Characterization of acute lymphoblastic leukemia MRD and relapse using single cell omics | Arif Kocak KU Leuven |
| DC6 | Multiomic and metabolomic characterization of AML residual disease after AZA/VEN treatment | Nishika Gupta INSERM |
| DC7 | Dissecting and targeting niche-dependent vulnerabilities of protection from therapy in AML | Thomas Henderson University of Sevilla |
| DC8 | Therapy-induced senescence as anti-cancer and immune-stimulatory strategy in AML | Maria Rodrigues Lopes Ospedale San Raffael |
| DC9 | Characterization of persisting leukemic blasts in down syndrome patients to define targets for immune-therapy | Matija Kovic Goete University |
| DC10 | Targeting MRD and LSCs in the bone marrow niche by chemokine modified, dual targeting CAR T cells in AML | Pierluigi Carulli LMU |



Integrated multi-angle research and training network to eradicate leukemia minimal residual disease MIRACLE-Leukemia is a Marie Skłodowska-Curie doctoral network and aims to combat MRD to improve leukemia treatment.

Marie Skłodowska-Curie Doctoral Networks (MSCA DN) are part of the European Union's Horizon Europe framework, designed to support the training and career development of early-stage researchers (doctoral candidates). These networks aim to enhance their skills, knowledge, and employability by offering innovative, collaborative, and interdisciplinary doctoral training programs.



miracle-leukemia.eu



[miracle-leukemia](https://www.linkedin.com/company/miracle-leukemia)